503414445 07/29/2015

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3461079

SUBMISSION TYPE:		1	NEW ASSIGNMENT				
NATURE OF CONVEYANCE:		ļ	ASSIGNMENT				
CONVEYING PARTY I	DATA						
		N	lame	Execution Date			
ASTRAZENECA UK LIMITED				07/17/2015			
RECEIVING PARTY D	ΑΤΑ						
Name:	ASTRA	ASTRAZENECA AB					
Street Address:	SE-151	85					
City:	SODEF	ODERTALJE					
State/Country:	SWEDE	SWEDEN					
PROPERTY NUMBER	S Total: 1						
Property Type			Number				
		103367	757				
CORRESPONDENCE	DATA						
CONNESPONDENCE							
		(617)64	46-1666				
Fax Number: <i>Correspondence will</i>	be sent to	the e-	46-1666 mail address first; if that is a at is unsuccessful, it will be s				
Fax Number: <i>Correspondence will using a fax number, i</i> Phone:	be sent to f provided	b the e- d; if tha 617-64	<i>mail address first; if that is a</i> It is unsuccessful, it will be a 6-1600				
Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email:	be sent to f provided	o <i>the e-</i> <i>1; if tha</i> 617-64 james.	mail address first; if that is a at is unsuccessful, it will be 6-1600 charlesworth@finnegan.com	sent via US N	lail.		
Fax Number: <i>Correspondence will using a fax number, in</i> Phone: Email: Correspondent Name	be sent to f provided :	o the e- d; if tha 617-64 james. FINNE	mail address first; if that is a at is unsuccessful, it will be 6-1600 charlesworth@finnegan.com GAN HENDERSON FARABO	sent via US N	lail.		
Fax Number: <i>Correspondence will using a fax number, in</i> Phone: Email: Correspondent Name Address Line 1:	be sent to f provided :	o the e- d; if tha 617-64 james. FINNE 2 SEAI	mail address first; if that is at is unsuccessful, it will be 6-1600 charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE	sent via US N	lail.		
Fax Number: <i>Correspondence will using a fax number, in</i> Phone: Email: Correspondent Name	be sent to f provided :	<i>the e-</i> <i>d; if tha</i> 617-64 james. FINNE 2 SEAI 6TH FL	mail address first; if that is at is unsuccessful, it will be 6-1600 charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE	sent via US M W GARRETT	lail.		
Fax Number: <i>Correspondence will</i> <i>using a fax number, in</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	be sent to f provided :	the e- d; if the 617-64 james. FINNE 2 SEA 6TH FI BOST	mail address first; if that is a at is unsuccessful, it will be 6-1600 charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE _OOR	sent via US M W GARRETT 0	lail.		
Fax Number: <i>Correspondence will</i> <i>using a fax number, in</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2:	be sent to f provided :	the e- d; if the 617-64 james. FINNE 2 SEAI 6TH FL BOST	mail address first; if that is at is unsuccessful, it will be charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE LOOR DN, MASSACHUSETTS 0221	sent via US M W GARRETT 0	lail.		
Fax Number: <i>Correspondence will</i> <i>using a fax number, in</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	be sent to f provided :	b the e- d; if that 617-64 james. FINNE 2 SEAI 6TH FL BOSTC	mail address first; if that is at is unsuccessful, it will be charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE LOOR DN, MASSACHUSETTS 0221	sent via US M W GARRETT 0	lail.		
Fax Number: <i>Correspondence will using a fax number, in</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 4: NAME OF SUBMITTER BIGNATURE:	be sent to f provided :	b the e- d; if that 617-64 james. FINNE 2 SEAI 6TH FL BOSTC	mail address first; if that is at is unsuccessful, it will be c6-1600 charlesworth@finnegan.com GAN HENDERSON FARABO PORT LANE LOOR DN, MASSACHUSETTS 0221 ELIZABETH SHAH, REG. NO. Elizabeth Shah/	sent via US M W GARRETT 0	lail.		

SOLE/JOINT INVENTION (U.S. Rights Only)

ASSIGNMENT

WHEREAS, AstraZeneca UK Limited, a corporation of United Kingdom, whose principle place of business is 2 Kingdom Street, London W2 6BD, United Kingdom (hereinafter referred to as Assignor), owns an invention entitled:

INHALATION DEVICE

for which an application for United States Letters Patent was filed on January 6, 2003 (Application No. 10/336,757), and for which a United States Letters Patent was issued on October 19, 2004 (Patent No. 6,805,116); and

WHEREAS, AstraZeneca AB, a corporation of Sweden, whose principle place of business is SE-151 85 Södertälje, Sweden (hereinafter referred to as Assignee), is desirous of securing the legal right, title, and interest in and to this invention in the United States, the above-referenced application for United States Letters Patent on this invention, and the Letters Patent issued upon the above-referenced application;

NOW THEREFORE, be it known that for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, We, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our legal right, title, and interest in and to this invention, the above-referenced application that discloses and claims this invention, and all divisions and continuations thereof, and all Letters Patent of the United States which have been or may be granted thereon, and all reissues thereof, and all extensions, renewals, and reissues thereof, and all rights to claim priority on the basis of this application; and We hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue all United States Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful caths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

County of	Cheshire, UK)))	Company: By: Name (Printed): Title:	AstraZeneca UK Limited Miceologica Lucy PADGET Senior Patent Director, Oncology and
			Date:	Asia iMed TT JULY QCIS
Witnessed	before me this	day of Tara Cooney	AstraZeneca Leo	al & Intellectual Property, Mereside, acclesfield, Cheshire, SK10 4TG, United

Page 1 of 1

RECORDED: 07/29/2015